Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

21. Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials Full Text available with Trip Pro

Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials Whether a loading dose of atorvastatin (80 mg) can reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) remains controversial. Therefore, we performed this meta-analysis.Randomized controlled trials (RCT) comparing (...) : 0.76, 95% CI 0.69-0.84) after more than 30 days. No significant differences were observed in death or stroke within 30 days or after more than 30 days.Our meta-analysis supports the concept that a loading dose of atorvastatin markedly reduces cardiovascular events in patients with ACS.Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

2019 EvidenceUpdates

22. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Seizures may be reduced in some severe drug-resistant epilepsies by a cannabis derivative Discover Portal Discover Portal Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol to their treatment may reduce seizure (...) , 306 participants). The likelihood of reducing seizure frequency by 50% or more was moderately increased (43.5% with cannabidiol vs 25.0% with placebo; RR 1.74, 95% CI 1.24 to 2.43; two trials, 291 participants). Parents or carers reported an improvement in their child’s overall quality of life (59.8% with cannabidiol vs 34.5% with placebo; RR 1.73, 95% CI 1.33 to 2.26, two trials, 274 participants). Any adverse events (88.4% with cannabidiol vs 69.7% with placebo; RR 1.24, 95% CI 1.13 to 1.36; 5

2019 NIHR Dissemination Centre

23. Benchmarking study helps hospitals improve measurement of adverse events

Benchmarking study helps hospitals improve measurement of adverse events Benchmarking study helps hospitals improve measurement of adverse events Discover Portal Discover Portal Benchmarking study helps hospitals improve measurement of adverse events Published on 20 June 2017 doi: One in ten inpatients in Welsh hospitals experienced an adverse event of some sort, about half of which were potentially preventable. This is very similar to the rate in other countries. The figures come from a review (...) of 4,388 patient records between October 2010 and March 2013. Welsh hospitals were using a screening tool at the time called the Global Trigger Tool to estimate rates of adverse effects. The tool surveys case notes of 20 inpatient records each month. Alongside the trigger tool process, researchers reviewed case notes using a more comprehensive two-step process – nurse screening followed by physician review – to compare how different the estimates were and to better understand how many events were

2019 NIHR Dissemination Centre

24. Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events

Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Discover Portal Discover Portal Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Published on 11 July 2017 doi: Adverse breathing events are about three times more common when using endotracheal tubes than laryngeal mask airways for infants under 12 months (...) complications than tubes. This Australian randomised controlled trial supported this, finding an adverse event rate of 53% with endotracheal tubes compared with only 18% with laryngeal mask airways. Conventional anaesthesia teaching advises the use of endotracheal tubes in infants even for relatively minor surgery, to provide a secure airway, but incidents may be more common when placing or removing the tube than a laryngeal mask. Share your views on the research. Why was this study needed? Over 8,000

2019 NIHR Dissemination Centre

25. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Full Text available with Trip Pro

Adverse events in people taking macrolide antibiotics versus placebo for any indication. Macrolide antibiotics (macrolides) are among the most commonly prescribed antibiotics worldwide and are used for a wide range of infections. However, macrolides also expose people to the risk of adverse events. The current understanding of adverse events is mostly derived from observational studies, which are subject to bias because it is hard to distinguish events caused by antibiotics from events caused (...) by the diseases being treated. Because adverse events are treatment-specific, rather than disease-specific, it is possible to increase the number of adverse events available for analysis by combining randomised controlled trials (RCTs) of the same treatment across different diseases.To quantify the incidences of reported adverse events in people taking macrolide antibiotics compared to placebo for any indication.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which includes

2019 Cochrane

26. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. Full Text available with Trip Pro

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. Higher baseline high-sensitivity C-reactive protein (hsCRP) levels after an acute coronary syndrome (ACS) are associated with adverse cardiovascular outcomes. The usefulness of serial hsCRP measurements for risk stratifying patients after ACS is not well characterized.To assess whether longitudinal increases in hsCRP (...) measurements during the 16 weeks after ACS are independently associated with a greater risk of a major adverse cardiac event (MACE), all-cause death, and cardiovascular death.Secondary analysis of the double-blind, multicenter, randomized clinical Vascular Inflammation Suppression to Treat Acute Coronary Syndromes for 16 Weeks (VISTA-16) trial conducted between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012), which included 5145 patients from 362 academic and community hospitals

2019 JAMA cardiology Controlled trial quality: predicted high

27. Adverse events related to coloured dye injections used in sentinel lymph node mapping - a systematic review

Adverse events related to coloured dye injections used in sentinel lymph node mapping - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

28. Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized control trials

Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized control trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

29. Predictors of medication related adverse events in wards inpatients

Predictors of medication related adverse events in wards inpatients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

30. Psychiatric adverse events associated with pregabalin: systematic review and meta-analysis

Psychiatric adverse events associated with pregabalin: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

31. The effect of preoperative psychological aspects on surgical outcomes and adverse events in oncological patients

The effect of preoperative psychological aspects on surgical outcomes and adverse events in oncological patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

32. Effect of nighttime surgery on mortality and adverse events: a systematic review and meta-analysis

Effect of nighttime surgery on mortality and adverse events: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

33. Statins reduce major adverse limb events and mortality in patients with peripheral artery disease. A systematic review and meta-analysis

Statins reduce major adverse limb events and mortality in patients with peripheral artery disease. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

34. Reporting of adverse events in randomized controlled trials of therapeutic exercise for knee osteoarthritis: a systematic review

Reporting of adverse events in randomized controlled trials of therapeutic exercise for knee osteoarthritis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

35. Adverse events in patients receiving placebo in phase III trials of biologics for psoriasis: a systematic review and meta-analysis

Adverse events in patients receiving placebo in phase III trials of biologics for psoriasis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

36. Adverse cardiac events of PD-1 and PD-L1 inhibitors in the treatment of cancer: a network meta-analysis

Adverse cardiac events of PD-1 and PD-L1 inhibitors in the treatment of cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

37. Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer: a systematic review and network meta-analysis

Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

38. The prevalence of pain, analgesics use and their adverse events in patients with chronic kidney disease: protocol for a systematic review

The prevalence of pain, analgesics use and their adverse events in patients with chronic kidney disease: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

39. Large-scale, national and institutional trends in adverse events over time: a systematic review of longitudinal retrospective patient record review studies

Large-scale, national and institutional trends in adverse events over time: a systematic review of longitudinal retrospective patient record review studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

40. Incidence of adverse events after peripheral administration of vasoactive agents: systematic review and meta-analysis

Incidence of adverse events after peripheral administration of vasoactive agents: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO